Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting,
postprandial and the overall mean glucose concentrations.
Aim 1.1: To compare the mean fasting, the mean weekly glucose and the standard deviation of
weekly blood glucose concentrations as recorded by continuous glucose monitoring prior to and
following 6 weeks and 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily. In
addition, the time spent at glucose concentrations >150 and 200mg/dl and <70 and <40 mg/dl
will also be compared.
Aim 1.2: To compare the postprandial glucose concentrations following a test meal before and
after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily. Glucose
concentrations will be measured as areas under the curve for the data obtained from the meal
challenge.
Aim 1.3: To compare HbA1c levels(glycated hemoglobin) before and after 12 weeks of treatment
with 0.6, 1.2 and 1.8 mg of liraglutide daily Hypothesis 2: Treatment with Liraglutide in
patients with type 1 diabetes decreases postprandial glucagon concentrations and increases
postprandial C-peptide concentrations.
Aim 2.1: To compare fasting and postprandial glucagon and C-peptide concentrations following
a test meal before and after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide
daily.
Hypothesis 3: Treatment with Liraglutide in patients with type 1 diabetes delays gastric
emptying.
Aim 3.1: To compare the gastric emptying as measured by acetaminophen absorption before and
after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily.